PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33091827-3 2021 Therefore, we identified the expression of eight genes closely associated with platinum and fluorouracil metabolism (RRM1, RRM2, RRM2B, POLH, DUT, TYMS, TYMP, MKI67) in the discovery cohort (N=291). Platinum 79-87 ribonucleotide reductase catalytic subunit M1 Homo sapiens 117-121 26842788-13 2016 RRM1 may be a prognostic and predictive biomarker for PFS in patients with NSCLC who received platinum-based adjuvant chemotherapy, and combining EGFR mutation and RRM1 expression or combining ERCC1 and RRM1 expression can enhance prognostic and predictive power for PFS. Platinum 94-102 ribonucleotide reductase catalytic subunit M1 Homo sapiens 0-4 26650486-5 2016 The aim of this study was to determine the association between single nucleotide polymorphisms (SNPs) of the RRM1 promoter (-37C>A, -524C>T) and the effectiveness of first-line chemotherapy based on platinum compounds and gemcitabine in NSCLC patients. Platinum 205-213 ribonucleotide reductase catalytic subunit M1 Homo sapiens 109-113 26715866-10 2015 Limited outcomes data support the use of mitotane and platinum therapies for patients with low levels of the proteins RRM1 and ERCC1. Platinum 54-62 ribonucleotide reductase catalytic subunit M1 Homo sapiens 118-122 26323924-0 2015 The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer. Platinum 91-99 ribonucleotide reductase catalytic subunit M1 Homo sapiens 16-42 26323924-1 2015 PURPOSE: Genetic polymorphisms of ribonucleotidereductase M1 (RRM1) was a DNA repair gene, which may affect patients" response to platinum-based chemotherapy or gemcitabine-based chemotherapy. Platinum 130-138 ribonucleotide reductase catalytic subunit M1 Homo sapiens 34-60 26323924-1 2015 PURPOSE: Genetic polymorphisms of ribonucleotidereductase M1 (RRM1) was a DNA repair gene, which may affect patients" response to platinum-based chemotherapy or gemcitabine-based chemotherapy. Platinum 130-138 ribonucleotide reductase catalytic subunit M1 Homo sapiens 62-66 26323924-2 2015 We retrospectively assessed whether single nucleotide polymorphisms (SNPs) of RRM1 can be used to predict overall survival (OS), progression free survival and response in nonsmall cell lung cancer (NSCLC) patients treated with platinum-based regimens as first-line chemotherapy. Platinum 227-235 ribonucleotide reductase catalytic subunit M1 Homo sapiens 78-82 26323924-8 2015 CONCLUSION: The genotype of RRM1 -269C > A was significantly associated with platinum-based chemotherapy sensitivity in smoking patients and can be used to predict OS in advanced NSCLC patients who received platinum-based chemotherapy or gemcitabine-based chemotherapy. Platinum 80-88 ribonucleotide reductase catalytic subunit M1 Homo sapiens 28-32 26323924-8 2015 CONCLUSION: The genotype of RRM1 -269C > A was significantly associated with platinum-based chemotherapy sensitivity in smoking patients and can be used to predict OS in advanced NSCLC patients who received platinum-based chemotherapy or gemcitabine-based chemotherapy. Platinum 210-218 ribonucleotide reductase catalytic subunit M1 Homo sapiens 28-32 26200905-11 2015 RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy. Platinum 111-119 ribonucleotide reductase catalytic subunit M1 Homo sapiens 0-4 26000095-7 2015 Significant correlation was detected between the ex vivo sensitivity to platinum based drugs and gemcitabine and the level of ERCC1 and RRM1. Platinum 72-80 ribonucleotide reductase catalytic subunit M1 Homo sapiens 136-140 21370501-0 2011 RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. Platinum 163-171 ribonucleotide reductase catalytic subunit M1 Homo sapiens 0-4 25227663-10 2014 This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the mRNA expression of BRCA1, ERCC1, RRM1, and RRM2. Platinum 41-49 ribonucleotide reductase catalytic subunit M1 Homo sapiens 151-155 25078585-1 2014 This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis. Platinum 112-120 ribonucleotide reductase catalytic subunit M1 Homo sapiens 53-57 24647522-2 2014 This retrospective study was performed to evaluate the predictive value of ribonucleotide reductase regulatory subunit M1 (RRM1) on the therapeutic efficacy of platinum-based chemotherapy in patients with NSCLC. Platinum 160-168 ribonucleotide reductase catalytic subunit M1 Homo sapiens 123-127 24155212-4 2014 The low expression of RRM1 and RRM2 significantly increased the platinum-based chemotherapy response (For RRM1: odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.38-3.18; For RRM2: OR = 1.64, 95% CI = 1.09-2.48). Platinum 64-72 ribonucleotide reductase catalytic subunit M1 Homo sapiens 22-26 24155212-4 2014 The low expression of RRM1 and RRM2 significantly increased the platinum-based chemotherapy response (For RRM1: odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.38-3.18; For RRM2: OR = 1.64, 95% CI = 1.09-2.48). Platinum 64-72 ribonucleotide reductase catalytic subunit M1 Homo sapiens 106-110 24155212-7 2014 In conclusion, low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in NSCLC. Platinum 98-106 ribonucleotide reductase catalytic subunit M1 Homo sapiens 33-37 24045016-2 2013 Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC. Platinum 171-179 ribonucleotide reductase catalytic subunit M1 Homo sapiens 83-110 24045016-2 2013 Based on the literature, excision repair cross complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) genes represent predictive biomarkers of response to platinum compound and gemcitabine, in NSCLC. Platinum 171-179 ribonucleotide reductase catalytic subunit M1 Homo sapiens 112-116 23982437-0 2013 Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Platinum 87-95 ribonucleotide reductase catalytic subunit M1 Homo sapiens 30-34 23982437-11 2013 The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine. Platinum 167-175 ribonucleotide reductase catalytic subunit M1 Homo sapiens 16-20 23401439-5 2013 Although low ERCC1 and/or RRM1 expression is generally associated with sensitivity to platinum, the results published in retrospective and prospective studies are not always consistent. Platinum 86-94 ribonucleotide reductase catalytic subunit M1 Homo sapiens 26-30 22330686-4 2012 Optimizing treatment according to tumor status for DNA-repair biomarkers, such as ERCC1, BRCA1 or RRM1, could predict response to platinum, taxanes and gemcitabine-based therapies, respectively, and might improve substantially the response of individual patients" tumors. Platinum 130-138 ribonucleotide reductase catalytic subunit M1 Homo sapiens 98-102 28920258-0 2012 Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer. Platinum 24-32 ribonucleotide reductase catalytic subunit M1 Homo sapiens 84-88 21370501-1 2011 OBJECTIVE: To evaluate the predictive values of gene expressions of ribonucleotide reductase M1 (RRM1) and breast cancer susceptibility gene 1 (BRCA1) in peripheral blood from Chinese patients with non-small-cell lung cancer (NSCLC) treated with gemcitabine plus platinum. Platinum 263-271 ribonucleotide reductase catalytic subunit M1 Homo sapiens 97-101 21370501-9 2011 Advanced NSCLC patients with low RRM1 expression levels may benefit from gemcitabine plus platinum therapy. Platinum 90-98 ribonucleotide reductase catalytic subunit M1 Homo sapiens 33-37 21370501-10 2011 RRM1 mRNA expression in peripheral blood could be used to predict the prognosis of NSCLC treated by gemcitabine and platinum. Platinum 116-124 ribonucleotide reductase catalytic subunit M1 Homo sapiens 0-4 18494946-1 2008 BACKGROUND AND OBJECTIVE: Expression of genes involved in DNA repair and/or DNA synthesis, including ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) has been reported to be associated with chemosensitivity to platinum agents and gemcitabine. Platinum 248-256 ribonucleotide reductase catalytic subunit M1 Homo sapiens 101-128 19304340-4 2009 This study was to investigate the relationship between polymorphisms of the RRM1 gene and sensitivity to platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Platinum 105-113 ribonucleotide reductase catalytic subunit M1 Homo sapiens 76-80 19552012-4 2009 A literature revision was done in order to define the role of ERCC1 e RRM1 genes in the response to chemotherapy based in platinum and gemcitabine respectively. Platinum 122-130 ribonucleotide reductase catalytic subunit M1 Homo sapiens 70-74 20719132-2 2009 It has been proven that ERCC1, RRM1, p53 expressions were related to resistance to platinum and prognosis of the patcents with lung cancer. Platinum 83-91 ribonucleotide reductase catalytic subunit M1 Homo sapiens 31-35 18520795-1 2008 HYPOTHESIS: Aim of the study was to quantify ERCC1, RRM1, and TopoIIalpha mRNA expression profile as predictive factors for response and survival in SCLC patients treated with platinum/etoposide. Platinum 176-184 ribonucleotide reductase catalytic subunit M1 Homo sapiens 52-56 18494946-1 2008 BACKGROUND AND OBJECTIVE: Expression of genes involved in DNA repair and/or DNA synthesis, including ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) has been reported to be associated with chemosensitivity to platinum agents and gemcitabine. Platinum 248-256 ribonucleotide reductase catalytic subunit M1 Homo sapiens 130-134 18494946-7 2008 CONCLUSIONS: These in vitro results suggest that further studies are needed to evaluate the expression of the RRM1, ERCC1 and ERCC2 genes as predictive biomarkers for sensitivity to platinum agents and gemcitabine. Platinum 182-190 ribonucleotide reductase catalytic subunit M1 Homo sapiens 110-114 16966686-11 2006 CONCLUSION: The results strongly suggest that tumoral RRM1 expression is a major predictor of disease response to gemcitabine/platinum chemotherapy. Platinum 126-134 ribonucleotide reductase catalytic subunit M1 Homo sapiens 54-58 16966686-0 2006 RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. Platinum 64-72 ribonucleotide reductase catalytic subunit M1 Homo sapiens 0-4